John Woodyear, MD
Family Medicine · Troy, NCNPI 1124110994
Payments from drug & device makers
Across 449 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Orexo US, Inc.$2K
- AbbVie$1K
- Lilly USA, LLC$913
- Novo Nordisk$760
- Gilead$687
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,25012%
- Food & beverage$8,77687%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $2,104 |
| Orexo US, Inc. | 15 | $1,640 |
| AbbVie(2 entities) | 102 | $1,364 |
| Lilly USA, LLC | 50 | $913 |
| Novo Nordisk | 61 | $760 |
| Gilead | 28 | $687 |
| Pfizer | 10 | $238 |
| Boehringer Ingelheim | 12 | $209 |
| Abbott | 6 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $197 |
| Daiichi Sankyo Inc. | 10 | $181 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| Mylan Specialty L.p. | 10 | $161 |
| GSK | 7 | $139 |
| Merck | 7 | $120 |
| Viatris Specialty LLC | 6 | $120 |
| Nestle Healthcare Nutrition Inc. | 5 | $118 |
| Indivior Inc. | 5 | $104 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $97 |
| Amgen | 5 | $86 |
| Biodelivery Sciences International, Inc. | 4 | $63 |
| Johnson & Johnson | 4 | $62 |
| Braeburn Inc. | 3 | $50 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Alkermes, Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Shield Therapeutics Inc | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Bioventus LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,032 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 54 | $65,367 |
| EliquisApixaban | 79 | $58,993 |
| JardianceEmpagliflozin | 47 | $49,971 |
| OzempicSemaglutide | 20 | $39,851 |
| FarxigaDapagliflozin Propanediol | 37 | $36,147 |
| EntrestoSacubitril/Valsartan | 20 | $23,083 |
| MounjaroTirzepatide | 14 | $22,621 |
| ZenpepLipase/Protease/Amylase | 14 | $21,930 |
| VraylarCariprazine Hcl | 12 | $20,434 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 64 | $18,904 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $18,252 |
| MyrbetriqMirabegron | 13 | $17,513 |
| LinzessLinaclotide | 16 | $14,816 |
| JanuviaSitagliptin Phosphate | 16 | $13,499 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 62 | $12,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $913 | $87,98868 claims |
| PfizerEliquis, Abrysvo | $238 | $77,896143 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,104 | $64,38795 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $209 | $59,34465 claims |
| Novo NordiskOzempic | $760 | $39,85120 claims |
| AbbVieVraylar, Linzess | $1,364 | $35,25028 claims |
| GSKShingrix, Trelegy Ellipta | $139 | $24,37076 claims |
| NovartisEntresto | $16 | $23,08320 claims |
| MerckJanuvia | $120 | $13,49916 claims |
| Johnson & JohnsonXarelto | $62 | $12,18514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Troy
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.